Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2017, Article ID 7610374, 7 pages
https://doi.org/10.1155/2017/7610374
Clinical Study

Baseline Renal Function Predicts Hyponatremia in Liver Cirrhosis Patients Treated with Terlipressin for Variceal Bleeding

1Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
2Department of Internal Medicine, Hallym University Gangdong Sacred Heart Hospital, Gangdong, Republic of Korea
3Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea
4Department of Internal Medicine, Hallym University Gangnam Sacred Heart Hospital, Seoul, Republic of Korea

Correspondence should be addressed to Jun Goo Kang; moc.sapme@4080gjk

Received 18 January 2017; Revised 5 July 2017; Accepted 30 July 2017; Published 17 September 2017

Academic Editor: Fabio Farinati

Copyright © 2017 Sung Eun Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. D’Amico, R. De Franchis, and Cooperative Study Group, “Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators,” Hepatology, vol. 38, pp. 599–612, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. G. D’Amico, J. C. Garcia-Pagan, A. Luca, and J. Bosch, “Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review,” Gastroenterology, vol. 131, pp. 1611–1624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. G. D’Amico, L. Pagliaro, and J. Bosch, “Pharmacological treatment of portal hypertension: an evidence-based approach,” Seminars in Liver Disease, vol. 19, pp. 475–505, 1999. View at Publisher · View at Google Scholar
  4. G. Garcia-Tsao and J. Bosch, “Management of varices and variceal hemorrhage in cirrhosis,” The New England Journal of Medicine, vol. 362, pp. 823–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. De Franchis and Baveno V Faculty, “Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension,” Journal of Hepatology, vol. 53, pp. 762–768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Garcia Tsao, A. J. Sanyal, N. D. Grace, W. Carey, the Practice Guideline Committee of the American Association for the Study of Liver Diseases, and the Practice Parameters Committee of the American College of Gastroenterology, “Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis,” Hepatology, vol. 46, pp. 922–938, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Dunwoodie and S. Jowett, “Terlipressin causing a hyponatraemic seizure,” Scandinavian Journal of Gastroenterology, vol. 42, p. 665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Hyun, Y. S. Seo, K. G. Lee et al., “Terlipressin-induced hyponatremic seizure,” Scandinavian Journal of Gastroenterology, vol. 45, pp. 501–504, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Solà, S. Lens, M. Guevara et al., “Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension,” Hepatology, vol. 52, pp. 1783–1790, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. J. Kang, E. J. Bae, K. Hwang et al., “Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis,” Springerplus, vol. 2, p. 519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. R. De Franchis and Baveno VI Faculty, “Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension,” Journal of Hepatology, vol. 63, pp. 743–752, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. H. Kim, J. K. Kim, S. Y. Mun et al., “A case of hyponatraemic seizure following terlipressin therapy for a variceal hemorrhage in a patient with liver cirrhosis,” Korean Journal of Medicine, vol. 87, pp. 323–327, 2014. View at Google Scholar
  13. A. Di Lelio, C. Cestari, A. Lomazzi, and L. Beretta, “Cirrhosis: diagnosis with sonographic study of the liver surface,” Radiology, vol. 172, pp. 389–392, 1989. View at Publisher · View at Google Scholar
  14. J. Bruix, M. Sherman, and Practice Guidelines Committee, American Association for the Study of Liver Diseases, “Management of hepatocellular carcinoma,” Hepatology, vol. 42, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Escorsell, L. Ruiz del Arbol, R. Planas et al., “Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study,” Hepatology, vol. 32, pp. 471–476, 2000. View at Publisher · View at Google Scholar
  16. F. Feu, L. Ruiz del Arbol, R. Bañares, R. Planas, and J. Bosch, “Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal bleeding study group,” Gastroenterology, vol. 111, pp. 1291–1299, 1996. View at Google Scholar
  17. G. H. Lo, W. C. Chen, H. M. Wang et al., “Low-dose terlipressin plus banding ligation versus low-dose terlipressin alone in the prevention of very early rebleeding of oesophageal varices,” Gut, vol. 58, pp. 1275–1280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Abid, W. Jafri, S. Hamid et al., “Terlipressin vs. octreotide in bleeding esophageal varices as an adjuvant therapy with endoscopic band ligation: a randomized double-blind placebo-controlled trial,” The American Journal of Gastroenterology, vol. 104, pp. 617–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. L. Holmes, D. W. Landry, and J. T. Granton, “Science review: vasopressin and the cardiovascular system part 1--receptor physiology,” Critical Care, vol. 7, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Forsling, L. A. Aziz, M. Miller, R. Davies, and B. Donovan, “Conversion of triglycylvasopressin to lysine-vasopressin in man,” The Journal of Endocrinology, vol. 85, pp. 237–244, 1980. View at Google Scholar
  21. H. Nádvorníková and O. Schück, “The influence of a single dose of vasopressin analogs on human renal potassium excretion,” International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol. 20, pp. 155–158, 1982. View at Google Scholar
  22. A. Krag, F. Bendtsen, E. Pedersen, N. Holstein-Rathlou, and S. Møller, “Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects,” American Journal of Physiology - Renal Physiology, vol. 295, pp. F1295–F1300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. “Chapter 9: infection-related glomerulonephritis,” Kidney International Supplements, vol. 2, pp. 200–208, 2012. View at Publisher · View at Google Scholar
  24. R. Bhimma and H. M. Coovadia, “Hepatitis B virus-associated nephropathy,” American Journal of Nephrology, vol. 24, pp. 198–211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. L. Deng, X. W. Song, H. J. Liang, C. Feng, Y. J. Sheng, and M. Y. Wang, “Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells,” World Journal of Gastroenterology, vol. 12, pp. 1752–1756, 2006. View at Google Scholar
  26. H. M. Choi, S. C. Kim, M. G. Kim, S. K. Jo, W. Y. Cho, and H. K. Kim, “Etiology and outcomes of anuria in acute kidney injury: a single center study,” Kidney Research and Clinical Practice, vol. 34, pp. 13–19, 2015. View at Publisher · View at Google Scholar · View at Scopus